Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Cassava Sciences Inc
(NQ:
SAVA
)
9.371
-4.159 (-30.74%)
Streaming Delayed Price
Updated: 10:25 AM EDT, Jul 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Cassava Sciences Inc
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
31
32
Next >
Why Is Cassava Sciences (SAVA) Stock Up Today?
November 14, 2022
Today's big move in Cassava Sciences and SAVA stock has many investors watching this company's trials closer than ever.
Via
InvestorPlace
12 Health Care Stocks Moving In Monday's Intraday Session
November 14, 2022
Gainers
Via
Benzinga
CASSAVA SCIENCES INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Cassava Sciences, Inc. - SAVA
November 11, 2022
From
Kahn Swick & Foti, LLC
Via
Business Wire
Is the Stock Market Open on Election Day 2022?
November 07, 2022
Investors are wondering if the stock market is open on Election Day this year as they seek out extra time to head to the polls!
Via
InvestorPlace
Cassava Sciences Has a Big Warning for SAVA Stock Short Sellers
November 07, 2022
SAVA stock is in the green after reporting earnings. The company also filed a lawsuit against short sellers, alleging misleading statements.
Via
InvestorPlace
Cassava Sciences: Q3 Earnings Insights
November 07, 2022
Cassava Sciences (NASDAQ:SAVA) reported its Q3 earnings results on Monday, November 7, 2022 at 09:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Cassava Sciences Reports Third Quarter Financial Results for 2022 and Business Updates
November 07, 2022
From
Cassava Sciences, Inc.
Via
GlobeNewswire
What the Latest Controversy Really Means for SAVA Stock
November 07, 2022
SAVA stock continues to be dogged by controversy, but the risk/reward proposition for this biotech largely remains the same.
Via
InvestorPlace
Cassava Sciences Files Lawsuit Against Perpetrators of “Short and Distort” Campaign
November 03, 2022
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Why Is Cassava Sciences (SAVA) Stock Down 10% Today?
November 02, 2022
SAVA stock is in the red after a piece from Probes Reporter accused Cassava of being involved with two undisclosed SEC investigations.
Via
InvestorPlace
A New Study Makes Cassava Sciences Stock an Interesting Buy
October 31, 2022
With the biotech firm moving forward with an open-label study of its Alzheimer's treatment simufilam, SAVA stock is one to watch.
Via
InvestorPlace
Cassava Sciences Announces Expansion of Leadership Team
October 27, 2022
From
Cassava Sciences, Inc.
Via
GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
October 24, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
Short Interest Sector Focus: Healthcare Sector
October 20, 2022
As of the close of business on Wednesday, 10/19, we captured the Top 10 Highest Short Interest % stocks within the Healthcare Sector. The average short interest for stocks within the Healthcare sector...
Via
Benzinga
Alzheimer’s Pipeline of New Treatments Race to Improve Quality of Life for Patients
October 20, 2022
Palm Beach, FL – October 20, 2022 – FinancialNewsMedia.com News Commentary – Last year, about 6.2 million people aged 65 and above living in America were suffering from Alzheimer’s disease, (AD) which...
Via
FinancialNewsMedia
CASSAVA SCIENCES INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Cassava Sciences, Inc. - SAVA
October 14, 2022
From
Kahn Swick & Foti, LLC
Via
Business Wire
SAVA Stock Alert: Cassava Sciences Extends Trial
October 13, 2022
SAVA stock is in focus after Cassava announced that it would begin an open-label study of its investigational Alzheimer's drug, simufilam.
Via
InvestorPlace
Cassava Sciences Announces Initiation of an Open-label Extension Study
October 13, 2022
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Don’t Let Misconduct Allegations Cloud Your Perception of SAVA Stock
October 11, 2022
It's easy to get mired in the controversy surrounding Cassava Sciences, but distracted SAVA stock traders might miss an opportunity.
Via
InvestorPlace
3 Alzheimer Stocks to Buy as the Race for a Cure Heats Up
October 06, 2022
Here is a look at three names that buy-and-hold investors may want to consider as the race to find a cure for Alzheimer's disease accelerates
Via
MarketBeat
Exposures
Product Safety
Why Revelation Biosciences Shares Are Trading Higher By 29%, Here Are 50 Stocks Moving In Thursday's Mid-Day Session
October 06, 2022
Gainers Statera Biopharma, Inc. (NASDAQ: STAB) rose 98% to $0.2777. Statera Biopharma was recently granted European patent number EP3206708 titled "Methods And Compositions For The Treatment Of...
Via
Benzinga
2 Signals to Watch Before Buying SAVA Stock
October 05, 2022
SAVA stock got ahead of itself in September, but if it continues to pull back, a solid entry point could emerge for this risky biotech play.
Via
InvestorPlace
EXCLUSIVE: Top 10 Stocks Searched On Benzinga Pro In September: Where Do Tesla, Apple, Bed Bath & Beyond Rank?
October 04, 2022
Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers.
Via
Benzinga
$100 Invested In Cassava Sciences 15 Years Ago Would Be Worth This Much Today
October 03, 2022
Cassava Sciences (NASDAQ:SAVA) has outperformed the market over the past 15 years by 3.29% on an annualized basis producing an average annual return of 9.08%. Currently, Cassava Sciences has a market...
Via
Benzinga
$1000 Invested In This Stock 20 Years Ago Would Be Worth $10,000 Today
September 30, 2022
Cassava Sciences (NASDAQ:SAVA) has outperformed the market over the past 20 years by 4.23% on an annualized basis producing an average annual return of 12.02%. Currently, Cassava Sciences has a market...
Via
Benzinga
How High Can SAVA Stock Go Once the Controversy Clears?
September 30, 2022
If a reproduced SEC letter concerning Cassava Sciences' clearance is legit, SAVA stock could head much higher.
Via
InvestorPlace
'Right Now, You've Still Got To Avoid The Stock,' Jim Cramer Says About This Aerospace Company
September 30, 2022
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Sherwin-Williams Co (NYSE: SHW) might go lower as the PE (price-to-earnings) multiple is still "way too high" on the stock.
Via
Benzinga
These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win
September 28, 2022
Via
Benzinga
Why Is Acumen (ABOS) Stock Up 95% Today?
September 28, 2022
Acumen Pharmaceuticals (ABOS) stock is rocketing higher on Wednesday but it's not due to any recent news from the company.
Via
InvestorPlace
What Is Going on With Silo Pharma (SILO) Stock Today?
September 28, 2022
Silo Pharma (SILO) stock is in the news Wednesday as investors react to the company uplisting shares to the Nasdaq Exchange.
Via
InvestorPlace
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
31
32
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.